Abstract
Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.
Keywords:
Europe; case control study; influenza; influenza vaccination; influenza vaccine effectiveness; multicentre study.
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Child
-
Child, Preschool
-
Europe / epidemiology
-
European Union
-
Female
-
Humans
-
Infant
-
Infant, Newborn
-
Influenza A Virus, H1N1 Subtype / immunology*
-
Influenza A Virus, H1N1 Subtype / isolation & purification
-
Influenza A Virus, H3N2 Subtype / immunology*
-
Influenza A Virus, H3N2 Subtype / isolation & purification
-
Influenza B virus / immunology*
-
Influenza B virus / isolation & purification
-
Influenza Vaccines / administration & dosage
-
Influenza Vaccines / adverse effects
-
Influenza Vaccines / immunology*
-
Influenza Vaccines / therapeutic use*
-
Influenza, Human / epidemiology
-
Influenza, Human / prevention & control*
-
Influenza, Human / virology
-
Male
-
Middle Aged
-
Pandemics / prevention & control
-
Seasons*
-
Treatment Outcome
-
Vaccination / statistics & numerical data